[Effect of naproxen sodium on serum concentrations of IL-1, IL-6, and TNF in patients with acute, purulent pharyngo-tonsillitis].
BACKGROUND
Cytokines produced by macrophages and neutrophils participate in the host's defense mechanism; in infectious processes. Interleukins such as LI-1, IL-6, and tumor necrosis factor (TNF) also have a role in these acute phase mechanisms.


OBJECTIVE
Assess the effect of sodium naproxen on the serum concentration of IL-1, IL-6 and TNF in acute infectious process. MATERIAL A METHODS: Eighteen patients with clinical diagnosis of acute purulent pharyngitis and/or tonsillitis were randomly assigned to one of two groups of 9 patients each.


RESULTS
The patients in the first group received sodium naproxen and those in the other group received placebo. Patients of both groups received procaine G penicillin. Patients in the group receiving sodium naproxen showed improvement of the infectious and febrile syndromes within 72 hours. Patients receiving placebo showed signs and symptoms; of the infections and febrile syndromes for more than three days.


CONCLUSIONS
Patients receiving treatment with sodium naproxen had a statistically significant reduction of the serum concentration of IL-1b as compared to basal and 72 h measurements; there were also statistically significant differences with respect to patients receiving placebo. IL-6 and TNF did not change in any of the groups. These results show that serum IL-1b levels dropped in both groups with a more striking reduction in the group receiving sodium naproxen , that also showed a faster improvement of the symptoms.
Salgado Legorreta
C
C
Centro Médico Nacional Siglo XXI, IMSS, México, DF.
Martínez Zurita
F
F
Alarcón Santos
G
G
Martínez Cairo
S
S
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000097:blood* / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood* / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009288:Naproxen / Q000494:pharmacology* / Q000627:therapeutic use; D010402:Penicillin G Procaine / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D010612:Pharyngitis / Q000188:drug therapy* / Q000473:pathology; D013492:Suppuration; D014069:Tonsillitis / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis* / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007375:Interleukin-1; D015850:Interleukin-6; D010406:Penicillins; D014409:Tumor Necrosis Factor-alpha; D010402:Penicillin G Procaine; D009288:Naproxen
Efecto del naproxeno sódico en las concentraciones séricas de IL-1, IL-6 y TFN en pacientes con faringoamigdalitis aguda purulenta.